Would you give additional chemotherapy to women with stage III HER2+ breast cancer who have a grossly suboptimal response to neoadjuvant TCHP x6?

It really would depend on the hormone receptor status of the patient. If a patient was ER positive, one may not expect a pCR from TCHP, and they may benefit from Neratinib extended therapy based on the ExteNET trial. The HR was 0.6 for IDFS for the patients that had tumors that were hormone receptor...